Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer
Authors:
- David DigomannDDDavid Digomann
- Charlotte ReicheCRCharlotte Reiche
- Antonia StammbergerASAntonia Stammberger
- Tido WillmsTWTido Willms
- Loreen S. RudekLRLoreen S. Rudek
- Jamie KölbelJKJamie Kölbel
- Felix MerbothFMFelix Merboth
- Loreen Natusch BufeLBLoreen Natusch Bufe
- Carolin BeerCBCarolin Beer
- Therés GolleTGTherés Golle
Open Access
Abstract
No abstract availableKeywords
Funding Information
- European Commission (03ZU1111LB)
- European Commission (01KT2304B)
- Deutsche Forschungsgemeinschaft (SE2980/5-1)
- Bundesministerium für Forschung, Technologie und Raumfahrt
- Else Kröner-Fresenius-Stiftung
- Deutschen Konsortium für Translationale Krebsforschung
- Deutsches Rote Kreuz
- Jung-Stiftung für Wissenschaft und Forschung
This publication has 55 references indexed in Scilit:
- A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)Genes & Diseases, 2023
- Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseasesBiochemical Pharmacology, 2023
- Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methodsEuropean Journal of Immunology, 2023
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling studyeClinicalMedicine, 2022
- Unconventional secretion of annexins and galectinsSeminars in Cell & Developmental Biology, 2018
- Clinical characteristics and prognostic significance of galectins for patients with gastric cancer: A meta-analysisInternational Journal of Surgery, 2018
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Prevention of Gastric CancerJAMA, 2014
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010